KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $26.6250.

Several brokerages have recently commented on KALV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Citizens Jmp dropped their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. JMP Securities upped their target price on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a report on Friday, September 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $13.92 on Thursday. The firm has a market capitalization of $703.60 million, a P/E ratio of -3.53 and a beta of -0.04. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $17.28. The company’s 50 day simple moving average is $12.08 and its 200-day simple moving average is $12.93.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. Sell-side analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Paul K. Audhya sold 5,296 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the transaction, the insider directly owned 131,831 shares of the company’s stock, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 10,940 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $147,143.00. Following the sale, the chief executive officer owned 416,189 shares of the company’s stock, valued at approximately $5,597,742.05. This represents a 2.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 31,329 shares of company stock worth $432,485 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in shares of KalVista Pharmaceuticals by 5.1% during the 1st quarter. Bank of New York Mellon Corp now owns 103,530 shares of the specialty pharmaceutical company’s stock worth $1,195,000 after purchasing an additional 4,983 shares in the last quarter. CWM LLC increased its holdings in KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 4,549 shares during the last quarter. Earned Wealth Advisors LLC bought a new position in KalVista Pharmaceuticals during the first quarter valued at approximately $44,000. Vanguard Group Inc. lifted its stake in KalVista Pharmaceuticals by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company’s stock valued at $26,526,000 after acquiring an additional 43,355 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in KalVista Pharmaceuticals by 12.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 113,124 shares of the specialty pharmaceutical company’s stock valued at $1,305,000 after acquiring an additional 12,776 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).